ClinicalTrials.gg

Program

mizagliflozin

Also written as “Mizagliflozin”, “Mizagliflozin 5 mg” and “Mizagliflozin 10 mg”.

Its studies are mostly in Hypoglycemia, led by Vogenx.

Furthest: phase 2, since Sep 8, 20223 company-led studies, 1 open or runningNext primary completion: Oct 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vogenx31 open or runningphase 2since Sep 8, 2022Sep 8, 2022Oct 2027phase 2 · NCT07760961

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 8, 2022First study: phase 2 study in Postbariatric HypoglycemiaFirst studyNCT05541939 · 9 enrolled · United States
  2. Jan 31, 2023Phase 2 study in Postbariatric HypoglycemiaNCT05721729 · 15 enrolled · United States
  3. Aug 7, 2026Phase 2 study in Postbariatric HypoglycemiaNCT07760961 · 36 planned · United States

Ahead

  1. Oct 2027Primary completion: phase 2 study in Postbariatric HypoglycemiaNCT07760961

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07760961Postbariatric Hypoglycemia · United States2RecruitingOct 202736
NCT05721729Postbariatric Hypoglycemia · United States2CompletedMay 1, 202415
NCT05541939Postbariatric Hypoglycemia · United States2CompletedFeb 17, 20239

How it is read

Names in the registry

  • “Mizagliflozin”, 2 entries
  • “Mizagliflozin 5 mg”, 1 entry
  • “Mizagliflozin 10 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.